Neuropsychobiology

 

The Evoked Potential in Pharmacopsychiatry

Saletu B.

Author affiliations

Section of Pharmacopsychiatry, Psychiatrische Universitätsklinik Wien (Chairman: Prof. Berner), Vienna

Related Articles for ""

Neuropsychobiology 1977;3:75–104

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: February 15, 2008
Issue release date: 1977

Number of Print Pages: 30
Number of Figures: 0
Number of Tables: 0

ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)

For additional information: https://www.karger.com/NPS

Abstract

Somatosensory, visual and auditory evoked potentials (EP) were recorded in different psychiatric populations before as well as during psychotropic drug treatment. Drug-free schizophrenic patients showed shorter latencies, smaller amplitudes and an increased intraindividual variability in their EP than controls. Psychotic children but also children of schizophrenic mothers (so-called high-risk children) exhibited similar differences as compared to controls, suggesting a CNS overarousal as the pathoneurophysiological sub-strate of schizophrenia. Shorter latencies were also seen in children of psychopathic fathers. Regression and correlation analysis of psychopathological and EP measurements in hyperkinetic children revealed the following findings: the shorter the latencies and the higher the amplitudes, the sicker was the child. During psychopharmacotherapy, significant changes occurred in the EP measurements, which were found to be significantly correlated with clinical improvement or deterioration. Neuroleptics induced a latency increase and an amplitude decrease in schizophrenic patients and psychotic children. Interestingly, amphetamine produced in hyperkinetic children a latency increase too, thus explaining the ‘paradoxical’ clinical response to amphetamine observed in these children. Differences between therapy-responsive and therapy-resistant patients are described and, finally, some data concerning the role of the pretreatment EP as a predictor of therapeutic outcome are discussed.

© 1977 S. Karger AG, Basel




Related Articles:


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: February 15, 2008
Issue release date: 1977

Number of Print Pages: 30
Number of Figures: 0
Number of Tables: 0

ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)

For additional information: https://www.karger.com/NPS


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP